Breast Tumour Size Measurement by Field Cycling Imaging

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07492043

Acronym

BREVIA

Enrollment

Registered

2026-03-25

Start date

2026-04-01

Completion date

2026-12-01

Last updated

2026-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Ductal Carcinoma In Situ

Keywords

Field-Cycling Imaging, FCI, DCIS, Breast Cancer

Brief summary

The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately estimate tumour size in patients with a type of breast cancer called ductal carcinoma in situ (DCIS). The main question it aims to answer is: Can FCI accurately estimate DCIS lesion size compared with histology results? Participants will have a standard MRI scan and an FCI scan before undergoing surgery to remove the tumour.

Interventions

OTHERField-Cycling Imaging research scan

Baseline FCI scan

OTHER3T MRI research scan

Baseline MRI scan

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Females ≥ 18 years old. * Subjects diagnosed with DCIS on initial biopsy. * Lesion size \>1 cm on imaging. * Subjects undergoing surgery as part of their treatment. * Able to fit comfortably in the scanners. * Able to understand written and spoken English.

Exclusion criteria

* Subjects undergoing chemotherapy or hormonal therapy. * Individuals unable to give informed consent. * Contra-indications to MRI scanning such as implantable cardiac devices. * Known allergy to contrast agent.

Design outcomes

Primary

Measure	Time frame	Description
Accuracy of DCIS lesion size estimation using FCI, validated against histopathological measurements (gold standard).	Baseline	Extent of agreement between lesion size estimation by FCI and actual lesion size according to NHS histopathology results.

Secondary

Measure	Time frame	Description
Comparison of DCIS lesion measurements using FCI and 3T MRI.	Baseline	Extent of agreement in lesion size measurements between FCI and conventional 3T MRI.

Countries

United Kingdom

Contacts

CONTACTVasiliki Mallikourti, PhD

vasiliki.mallikourti@abdn.ac.uk+44 1224 437831

STUDY_CHAIRVasiliki Mallikourti, PhD

University of Aberdeen

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026